EnglishУкраїнська
  • Main
  • Useful links
  • Information for Contributors
  • About
  • Editorial board

  • Article
    Dorofeyev А. E., Кyryan Е. А.

    SOME GENETIC PREDICTORS OF BOWEL PATHOLOGY DEVELOPMENT


    About the author: Dorofeyev А. E., Кyryan Е. А.
    Heading CLINICAL MEDICINE
    Type of article Scentific article
    Annotation Aim of this study was to analize genetic predispositivity on toll-like receptors genes mutations in patients with inflammatory bowel diseases (IBD). 92 patients with inflammatory bowel diseases were examined. Among them 54 (58.7%) patients with ulcerative colitis and 38 (41. 3%) patients with Crohn’s disease were observed. In all patients DNA diagnostic with analysis of mutations toll-like receptor 3 - TLR3 (mutation Phe412Leu) and toll-like receptor 4 – TLR4 (mutation Asp299Gly) were performed. In majority of IBD patients - 60 (65,2%) genetic predisposition to bowel pathology were observed. At the same time, TLR-3 polymorphism in ulcerative colitis patients were found more often, but TLR-4 mutations in Crohn’s disease patients more often were observed.Presents of toll-like receptors mutations correlated with more severe form of diseases and more exten.
    Tags IBD, Toll-like receptor mutation
    Bibliography
    • Dorofeyev A. E. Izmeneniya ekspressii MUC2, MUC3, MUC4, TFF3 v slizistoy obolochke tolstogo kishechnika u bolnyih nespetsificheskim yazvennyim kolitom / A. E. Dorofeyev, I. V. Vasilenko, O. A. Rassohina // Gastroenterologiya. – 2013. - No1 (47).
    • Karmakova T. A. Mutsin MUC1 kak biologicheskiy marker v morfologicheskih i serologicheskih issledovaniyah u onkologicheskih bolnyih: avtoref. dis. na zdobuttya nauk. stupenya doktora biol. nauk.: spets. «onkologiya» 14.01.12 / T. A. Karmakova – M., - 2014. – 27 s.
    • Fadeyenko G. D. Dostizheniya genetiki i genomiki v gastroenterologii / G. D. Fadeenko, A. S. Popovich // Zdorovya Ukrayiny. – Tematichniy nomer, berezen - 2014. – S. 20 – 21.
    • Albrecht H. 3rd.MUC1 and MUC4: switching the emphasis from large to small / H. Albrecht, K. L. Carraway // Cancer. Biother. Radiopharm. - 2011 Vol. 26(3). P.261-271.
    • Inagaki Y. Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers / Y. Inagaki, H. Xu, M. Nakata [et al.] // Biosci. Trends. - 2009. Vol. 3(6). P.220-232.
    • Kyo Y. Antiinflammatory role of MUC1 mucin during infection with nontypeable Haemophilus influenzae / Y. Kyo, K. Kato, Y.S. Park [et al.] // Am. J. Respir. Cell. Mol. Biol. - 2012. Vol. 46(2). P.149-156.
    • McGuckin M. A. Muc1 mucin limits both Helicobacter pylori colonization of the murine gastric mucosa and associated gastritis / M. A. McGuckin, A. L. Every, C. D. Skene [et al.] // Gastroenterology. - 2007. Vol. 133(4). P.1210–1218.
    • McAuley J. L. MUC1 cell surface mucin is a critical element of the mucosal barrier to infection / J. L. McAuley, S. K. Linden, C. W. Ping [et al.] // J. Clin. Invest. - 2007. Vol. 117(8) P 2313–2324.
    • Mc Guckin M. A. Intestinal barrier dysfunction in inflammatory bowel diseases / M. A. Mc Guckin, R. Eri, L. A. Simms [et al.] // Inflam. Bowel Dis. – 2009. - №15. – P. 100 – 113.
    • Rubin B.K.Mucus and mucins // B.K.Rubin Otolaryngol. Clin. North. Am. - 2010. - Vol. 43,(1). - P.27-34.
    • Ueno K. MUC1 mucin is a negative regulator of toll-like receptor signaling / K. Ueno, T. Koga, K. Kato [et al.] // Am. J. Respir. Cell. Mol. Biol. - 2008. Vol. 38(3). P.263–268.
    • Williams O.W. Airway mucus: From production to secretion / O. W. Williams, A. Sharafkhaneh, V. Kim [et al.] // Am. J. Respir. Cell Mol. Biol. - 2006. - Vol.34 (5). - P.527-536.
    Publication of the article «World of Medicine and Biology» №4(47) 2 part 2014 year, 031-034 pages, index UDK 616.34:575.191